FDA Approves First Menin Inhibitor for Acute Leukemia
The FDA granted full approval to the menin inhibitor revumenib (Revuforj) for adults and children 1 year and older with ...
Day: November 15, 2024
Medical Groups Wary of RFK Jr. Nom to Lead HHS
Some public health and medical organizations are expressing concern over President-elect Donald Trump’s nomination of Robert F. Kennedy, Jr. to ...
Clozapine’s REMS Program on the Chopping Block at Upcoming FDA Meeting
Is a risk evaluation and mitigation strategy (REMS) still needed for clozapine? That's what a joint meeting of two FDA ...
Physician Groups Quiet on RFK Jr. Nomination for HHS Secretary
The response from physician groups to President-elect Donald Trump's nomination of Robert F. Kennedy Jr. for HHS secretary has been ...
Higher BP Linked to Faster Visual Field Progression in Glaucoma
Higher mean blood pressure (BP) levels were associated with faster rates of visual field progression in patients with glaucoma, according ...
A Potential Reason Behind COVID Vaccines’ Waning Benefit
The inability of COVID vaccines to reach the long-lived plasma cell compartment in the bone marrow may explain their waning ...
Response Duration After Stopping Enfortumab Vedotin in Bladder Cancer
Patients with metastatic urothelial carcinoma who achieved a complete response after more than 8.5 months of single-agent enfortumab vedotin (Padcev) ...
MEK Inhibitor Scores Big Win in Adults, Children With Neurofibromatosis Type 1
Almost half of adults and children with neurofibromatosis type 1 (NF1) responded to the investigational MEK inhibitor mirdametinib, a large ...
How Often Do Doctors Use New Weight-Loss Drugs in Kids?
This story is part of a series called "Ozempic: Weighing the Risks and Benefits." It was produced in part through ...
NMO Drug Looks Good for IgG4-Related Disease
WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for neuromyelitis optica (NMO), in a ...
Europe Rejects Cinainu (Alopecia) & Kizfizo (Neuroblastoma)
Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended refusal of marketing authorizations for:Cinainu (allium/citrus/Paullinia/cacao), an herbal medicine ...
An Update on Therapeutics for COVID-19
Although the general population now has at least some immunity against COVID-19, the consequences of severe disease are frequently overlooked ...
EMA Recommends Vilobelimabfor ARDS Induced by SARS-CoV-2
Following a consultation with its emergency task force, the European Medicines Agency (EMA) has backed a drug for adult patients ...
Betsi move some vascular surgeries to England after ‘incident’
Getty ImagesA major surgery which between 10 and 15 patients have each year at Ysbyty Glan Clwyd will no longer ...
Two Lung Cancer Drugs Recommended by EMA
The European Medicines Agency (EMA) recommended eight medicines for approval this month, including two cancer drugs for treating non-small cell ...
Group Sues Tennessee Over Racial Requirements for Medical Boards
A nonprofit dedicated to opposing diversity initiatives in medicine has filed a federal lawsuit challenging the requirements surrounding the racial ...
Nurse Suicides High During the Pandemic, but Feared Surge Never Materialized
Female nurses' suicide risk remained higher but didn't worsen through the COVID-19 pandemic compared with other women, according to a ...
Leqembi Okayed for Subset of Early Alzheimer’s Patients
The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for Leqembi ...
Big Comeback for Myeloma Drug; DIY Cancer Therapy; Gut Clues to Bladder Cancer
GSK announced that belantamab mafodotin (Blenrep) plus bortezomib (Velcade) and dexamethasone improved overall survival in relapsed/refractory multiple myeloma as compared ...
MedPod Today: What Happens to Healthcare Under Trump?
The following is a transcript of the podcast episode: Rachael Robertson: Hey, everybody. Welcome to MedPod Today, the podcast series ...
